BJP MLA from Gorakhpur calls Poonawalla a dacoit, asks govt to acquire SII

Radha Mohan Das Agarwal compared Serum Institute of India (SII), CEO, Adar Poonawalla with a 'dacoit' and also asked the government to 'acquire' the company under the Epidemic Diseases Act

Adar Poonawalla, CEO, Serum Institute
Adar Poonawalla, CEO, Serum Institute of India
IANS Gorakhpur
1 min read Last Updated : Apr 23 2021 | 10:17 AM IST

Radha Mohan Das Agarwal, a senior BJP MLA from Gorakhpur, has compared Serum Institute of India (SII), CEO, Adar Poonawalla with a 'dacoit' and also asked the government to 'acquire' the company under the Epidemic Diseases Act.

Agarwal is upset over anti-coronavirus vaccine pricing.

The SII, on Wednesday, announced a price of Rs 600 per dose for Covishield supplies to private hospitals and Rs 400 per dose to state governments.

"@adarpoonawalla you are worse than a dacoit. @PMOIndia @AmitShah @blsanthosh @drharshvardhan should acquire your factory under epidemic act," the MLA, who is also a doctor, said in a tweet.

The MLA said, "Poonawalla should be allowed maximum profit of Cost + 50 per cent. Cost is Rs 220 so how can he sell at Rs 600 to general public?"

The vaccine maker announced pricing of AstraZeneca shots it manufactures at its Pune facility, following the government decision to open up inoculation to all citizens above 18 years of age.

--IANS

amita/sdr/

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineSerum Institute of India

First Published: Apr 23 2021 | 10:13 AM IST

Next Story